Skip to main content
. 2022 Mar 17;21(13):1391–1405. doi: 10.1080/15384101.2022.2051971

Table 2.

Clinical features between cisplatin-sensitive group and cisplatin-resistant group of lung adenocarcinoma

Term Sensitive group (n = 18) Resistant group (n = 20)
Sex    
Male 10 11
Female 8 9
TMN stage    
IIIb 11 12
IV 7 8
Histological degree    
Poor 4 5
Moderate 9 10
High 5 5
Lymph node metastasis    
Yes 8 6
No 10 14
Smoking    
Yes 5 6
No 13 14